РЕФРАКТЕРНАЯ МИГРЕНЬ: СОВРЕМЕННЫЕ МЕТОДЫ ЛЕКАРСТВЕННОЙ ТЕРАПИИ


Цитировать

Полный текст

Аннотация

Описаны современные методы лекарственной терапии рефрактерной мигрени, являющейся клинической разновидностью мигрени, при которой отмечается отсутствие или минимальный эффект стандартной терапии с доказанной эффективностью как для профилактики приступов, так и для их купирования. В связи с этим наибольшие трудности для неврологов представляет тактика ведения этой категории труднокурабельных пациентов. В основе долговременного и устойчивого клинического улучшения при рефрактерной мигрени лежит мультидисциплинарный подход при сочетании рациональной комбинированной фармакотерапии с большим спектром нелекарственных методов воздействия.

Об авторах

Евгения Викторовна Екушева

Первый Московский государственный медицинский университет им. И.М.Сеченова

Email: ekushevaev@mail.ru
лаборатория патологии вегетативной нервной системы НИО неврологии НИЦ 119991, г.Москва, ул. Трубецкая, д. 8, стр. 2

Игорь Владимирович Дамулин

Первый Московский государственный медицинский университет им. И.М.Сеченова

Email: damulin@mmascience.ru
кафедра нервных болезней и нейрохирургии 119991, г.Москва, ул. Трубецкая, д. 8, стр. 2

Список литературы

  1. Азимова Ю.Э., Маргулис М.И., Табеева Г.Р. Рефрактерная мигрень: от патогенеза к рациональной терапии // Русский медицинский журнал. 2011. № 1. С. 18-19.
  2. Екушева Е.В. Оптимальные подходы к купированию приступа мигрени: прошлое, настоящее и будущее // Русский медицинский журнал. 2012. № 10. С. 522-528.
  3. Екушева Е.В., Филатова Е.Г. Залдиар в лечении приступов мигрени // Журнал невролог. и психиатр. им. С.С. Корсакова. 2007. № 107. С. 74-76.
  4. Филатова Е.Г., Вейн А.М. Мигрень // Consilium medicum. 1999. № 1(2). С. 60-65.
  5. Яхно H.H., Орлова O.P., Артеменко А.Р. и др. Лечение головных болей препаратом лантокс. Медицинская технология. Разрешение на применение новой медицинской технологии. ФС №2008/288. Москва, 2008. 28 с.
  6. Ashina S., Serrano D., Lipton R.B. et al. Depression and risk of transformation of episodic to chronic migraine // J. Headache Pain. 2012. Vol. 13. P. 615-624.
  7. Ashkenazi A., Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes // Arch. Neurol. 2008. Vol. 65(1). P. 146-149.
  8. Ashkenazi A., Benlifer A., Korenblit J. et al. Zonizamide for migraine prophpylaxis inrefractory patients // Cephalalgia. 2006. Vol. 26. P. 1199-1202.
  9. Aurora S.K., Silberstein S.D., Kori S.H. et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine // Headache. 2011. Vol. 51. P. 507-517.
  10. Aurora S.K., Dodick D.W., Turkel C.C. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial // Cephalalgia. 2010. Vol. 30(7). P. 793-803.
  11. Bermejo P.E., Dorado R. Zonizamide for migraine prophylaxis in patients refractory to topiramate // Clin. Neuropharmacol. 2009. Vol. 32. P. 103-106.
  12. Bigal M.E., Rapoport A., Sheftell F. et al. Memantine in the preventive treatment of refractory migraine // Headache. 2008. Vol. 48. P. 1337-1342.
  13. Blumenfeld A., Silberstein S.D., Dodick D.W. et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program // Headache. 2010. Vol. 50(9). P. 1406-1418.
  14. Cady R.K., Schreiber C.P., Porter J.A. et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine // Headache. 2011. Vol. 51. P. 21-32.
  15. Diener H.C., Dodick D.W., Aurora S.K. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial // Cephalalgia. 2010. Vol. 30 (7). P. 804-814.
  16. Dodick D.W., Turkel C.C., DeGryse R. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program // Headache. 2010. Vol. 50. P. 921-936.
  17. Dodick D.W. Reflections and speculations on refractory migraine: why do some patients fail to improve with currently available therapies // Headache. 2008. Vol. 46(6). P. 828-837.
  18. Dodick D.W. Triptan nonresponder studies: implications for clinical practice // Headache. 2005. Vol. 45. P. 156-162.
  19. Dodick D.W., Mauskop A., Elkind A.H. et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study // Headache. 2005. Vol. 45(4). P. 315-324.
  20. Evans R.W. A rational approach to the management of chronic migraine // Headache. 2013. Vol. 53. P. 168-176.
  21. Gerwin R.R. Treatment of chronic migraine headache with onabotulinumtoxinA // Curr. Pain Headache Rep. 2011. Vol. 15(5). P. 336-338.
  22. Goadsby P.J., Schoenen J., Ferrari M.D. et al. Towards a definition of interactable headache for use in clinical practice and trials // Cephalalgia. 2006. Vol. 26. P. 1168-1170.
  23. Ifergane G., Wirguin I., Shvartzman P. Triptans - Why once? // Headache: The Journal of Head and Face Pain. 2006. Vol. 46(8). P. 1261-1263.
  24. Irimia P., Palma J.A., Fernandez-Torron R., Martinez-Vila E. Refractory migraine in a headache clinic population // BMC Neurol. 2011. Vol. 11. P. 94-98.
  25. Katsarava Z., Schneeweiss Kurth T., Kroener U. et al. Incidence and predictors for chronicity of headache in patients with episodic migraine // Neurology. 2004. Vol. 62. P. 788-790.
  26. Krusz J.C. Belanger J., Cagle J. Treatment of refractory migraines: high success rate in the clinic. Poster Abstract. 49th Annual Scientific Meeting of the American Headache Society. Chicago // Headache. 2007. Vol. 47. P. 752.
  27. Krymchantowski A.V., Jevoux C.C. Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy // Headache. 2012. Vol. 52(1). P. 129-132.
  28. Krymchantowski A.V., Jevoux C.С., Moreira P.F. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine // Pain Med. 2010. Vol. 11(1). P. 48-52.
  29. Krymchantowski A, Jevoux C.С. Memantine in the preventive treatment for migraine and refractory migraine // Headache. 2009. Vol. 49. P. 481-482.
  30. Krymchantowski A.V., Barbosa J.S. Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug // Arq. Neuropsiquiatr. 2001. Vol. 59(3-В). P. 708-711.
  31. Levin M. Opioids in headache // Headache. 2013. Vol. 48(6). P. 783-790.
  32. Levin М., Schulman Е. Refractory migraine: definition and classification. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 19-34.
  33. Lipton R.B., Bigal M.E. Epidemiology of refractory migraine. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 35-45.
  34. Lipton R.B., Silberstein S.D. The role of headache-related disability in migraine management: implications for headache treatment guidelines // Neurology. 2001. Vol. 56 (6, suppl. 1). P. S35-S842.
  35. Lovell B.V., Marmura M.J. New therapeutic developments in chronic migraine // Curr. Opin. Neurol. 2010. Vol. 23. P. 254-258.
  36. Magalhaes E., Menezes C., Cardeal M. et al. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine // Clin. Neurol. Neurosurg. 2010. Vol. 112(6). P. 463-466.
  37. Maizels M. Clonazepam for refractory headache: three cases illustrative of benefit and risk // Headache. 2010. Vol. 50, P. 650-656.
  38. Matak I., Bach-Rojecky L., Filipovic B. et al. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A // Neuroscience. 2011. Vol. 186. P. 201-207.
  39. Mathew N.T. Prophylactic treatment of refractory migraine. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 101-116.
  40. Mathew N.T., Jaffri S.F. A double-blind comparison of onabotulinumtoxinА (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study // Headache. 2009 Vol. 49. P. 1466-1478.
  41. McGeeney B.E. Acute and urgent treatment of refractory migraine. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 116-136.
  42. Nagy A.J., Gandhi S., Bhola R. et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches // Neurology. 2011. Vol. 77. P. 1827-1832.
  43. Oterino A., Ramon C., Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks // J. Headache Pain. 2012. Vol. 12. P. 235-238.
  44. Palmisani S., Al-Kaisy A., Arcioni R. et al. A six year retrospective review of occipital nerve stimulation practice - controversies and challenges of an emerging technique for treating refractory headache syndromes // J. Headache Pain. 2013. Vol. 14 (1). P. 67-72.
  45. Pascual-Gomez J., Gracia-Naya M., Leira R. et al. Zonisamide in the preventive treatment of refractory migraine // Rev. Neurol. 2010. Vol. 50. P. 129-132.
  46. Rapoport A.M., Bigal M.E., Volcy M. et al. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases // Headache. 2003. Vol. 43(5). P. 482-489.
  47. Robbins L. Refractory chronic migraine: longterm follow-up using a refractory rating scale // J. Headache Pain. 2012. Vol. 13. P. 225-229.
  48. Robbins L. Refractory chronic migraine // Рract. Pain Manag. 2010. Vol. 10. P. 10-24.
  49. Robbins L. Long-acting opioids for refractory chronic migraine // Pract. Pain Manag. 2009. Vol. 9(6). P. 74-78.
  50. Robertson C.E., Garza I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine // Neuropsych. Dis. Treatm. 2012. Vol. 8. P. 35-48.
  51. Rothrock J.F. Treatment refractory migraine: the case for opioid therapy // Headache. 2008. Vol. 48. P. 850-854.
  52. Saper J.R., Lake A.E. Inpatient Strategies for Refractory Migraine. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 314-341.
  53. Scher A.I., Stewart W.F., Ricci J.A. et al. Factors associated with the onset and remission of chronic daily headache in a population-based study // Pain. 2003. Vol. 106. P. 81-89.
  54. Schulman E.A., McGeeney B.E. Current concepts in refractory migraine // Curr. Treat. Opitions Neurol. 2013. Vol. 15(1). P. 40-55.
  55. Schulman Е. Historical overview of refractory headachе. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 5-18.
  56. Schulman E.A., Peterlin B.L., Lake A.E. et al. Defining refractory migraine: results of the RHSIS survey of American headache society members // Headache. 2009. Vol. 49. P. 509-518.
  57. Schulman E.A., Lake A.E., Goadsby P.J. et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American headache society // Headache. 2008. Vol. 48. P. 778-782.
  58. Schulman E.A., Traumuta G. Refractory headache // Headache. 1993. Vol. 33. P. 273-286.
  59. Sheftell F.D., Rapoport A.M., Tepper S.J. et al. Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study // Headache. 2005. Vol. 45(10). P. 1400-1406.
  60. Silberstein S.D., Dodick D.W., Saper J. et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study // Cephalalgia. 2012. Vol. 32. P. 1165-1179.
  61. Silberstein S.D., Dodick D.W., Pearlman S. Defining the pharmacologically interactable headache for clinical trials and clinical practice // Headache. 2010. Vol. 50. P. 1499-1506.
  62. Silberstein S.D., Stark S.R., Lucas S.M. et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial // Mayo Clin. Proc. 2005. Vol. 80(9). P. 1126-1137.
  63. Tepper S.J., Tepper D.E. Medication overuse headache in refractory migraine and its treatment. In: Refractory migraine. Mechanisms and management. Schulman E.A., Levin M., Lake A.E. et al. New York: Oxford University Press, 2010. P. 136-160.
  64. Tepper S.J., Bigal M.E., Sheftell F.D. et al. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases / Headache. 2004. Vol. 44(8). P. 794-800.
  65. Tobin J., Filtman S. Occipital nerve blocks: when and what to inject? // Headache. 2009. Vol. 49. P. 1521-1533.
  66. Togha M., Rahmat J.M. et al. Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate // J. Headache Pain. 2008. Vol. 9. P. 77-82.
  67. Wang S.J, Fuh J.L, Lu S.R. et.al. Quality of life differs among headache diagnoses: analysis of SF 36 survey in 901 headache patients // Pain. 2001. Vol. 89. P. 285-292.
  68. Weibelt S., Andress-Rothrock D., King W. et al. Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcome // Headache. 2010. Vol. 50. P. 1041-1044.

© Екушева Е.В., Дамулин И.В., 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах